Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Latest Information Update: 09 May 2025
At a glance
- Drugs Girentuximab I-124 (Primary) ; Pazopanib; Sunitinib
- Indications Renal cell carcinoma
- Focus Diagnostic use
Most Recent Events
- 02 May 2025 Planned End Date changed from 1 Apr 2025 to 1 Apr 2026.
- 02 May 2025 Planned primary completion date changed from 1 Apr 2025 to 1 Apr 2026.
- 01 May 2024 Planned End Date changed from 1 Apr 2024 to 1 Apr 2025.